Controlled release contraceptive devices: a status report

Journal of Controlled Release

Volumn 22, Issue 1, 1992, Pages 35-46

  Sam, A P ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Contraceptive device; Intra uterine device; Intravaginal ring; Subdermal implant

Indexed keywords

CONTRACEPTIVE AGENT; COPPER; COPPER INTRAUTERINE DEVICE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIMETICONE; ESTROGEN; ETHINYLESTRADIOL; ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; POLYCAPROLACTONE; POLYETHYLENE; PROGESTERONE; SILASTIC;

CONTRACEPTIVE DEVICE; DRUG ADMINISTRATION; DRUG RELEASE; FEMALE; HUMAN; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAVAGINAL DRUG ADMINISTRATION; PHARMACEUTICS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; VAGINA RING;

EID: 0026666036     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(92)90114-7     Document Type: Article

References (48)

1. Need for acceptability of long-acting steroida) contraception
2. Technologie pharmaceutique et contraception
3. Polymeric controlled drug delivery
4. Controlled release systems for contraception
5. Controlled-release contraceptive devices
6. Intravterine contraceptive devices
7. Long-term retease of copper from two Multiload IUD models: MLCuZSO and MLCu375
8. Copper corrosion and life span of IUDs (ML Cu 25O)
9. The effect of intrauterine progesterone on the hypothalamic-hypophy-seal-ovarian axis in humans
10. Progestasert: a uterine therapeutic system for long-term contraception.I. Philosophy and clinical efficacy
11. Plasma concentrations of levonorgestret as a function of the release rate of levonorgestrel from medicated inirauterine devices
12. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device
13. Intrauterine release of levonorgestrel
14. Design and clinical properties of the contraceptive subdermal implant Norplante®
15. Implantable levonorgestrel rod systems: in vivo release rates and clinical effects
16. Long-acting steroidal contraception: an update
17. International experience with Norplante® and NorpIantoe®-2 contraceptives
18. Development of a new long-acting contraceptive subdermal implant releasing 3-ketodesogestrel
19. The effect of a biodegradable contraceptive capsule (Capronor®) containing levonorgestrel on gonadotfopin, estrogen and progesterone levels
20. Phase H — clinical trial with biodegradable subdermal contraceptive implant Capronor® (4.0-cm single implant)
21. In vitro and in vivo release of levonorgestrel from poly(ortho esters). II. Crosslinked polymers
22. Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: phase I clinical study
23. Contraceptive efficacy of bioabsorbable pellets of norethindrone (NET) as subcutaneous implants: phase II clinical study
24. Biodegradable hollow fibres for the controlled release of hormones
25. Biodegradable hollow fibers for the controlled release of drugs
26. Reproducibility studies on microencapsulation of steroids in biodegradable polymers
27. Present status of contraceptive vaginal rings
28. Synthetic polymers in modern pharmacy
29. Contraceptive vaginal ring-a rising star on the contraceptive horizon
30. The acceptability of the contraceptive vaginal ring
31. Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries
32. Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation: Microdose intravaginal levonorgestrel contraception: a muliicentered clinical trial. I. Efficacy and side effects
33. Fabrication and testing of vaginal contraceptive devices designed for release of prespecified dose levels of steroids
34. Pharmacokinetic studies with a vaginal delivery system releasing levonorgestrel at a near zero order rate for one year
35. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestre] at a constant, near zero order rate
36. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel
37. Injectables and implants
38. A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids
39. The clinical acceptability of a non-medicated vaginal ring
40. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings
41. 3-Ketodesogestrel, ethinylestradiol vaginal rings for contraception
42. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel
43. Controlled release systems for contraception
44. A contraceptive vaginal ring releasing ethinylestradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry